Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 17/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 17/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.97 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.97 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.97 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | BRD4 | O60885 | 1/20 | 0.70 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | LTA4H | P09960 | 1/20 | 0.70 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635263 | 0.91 | HDAC1 (0.83) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL517697 | 0.91 | HDAC3 (0.86) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL19605418 | 0.86 | HDAC1 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL19605450 | 0.86 | HDAC1 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL17252159 | 0.86 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL5968936 | 0.86 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL1064449 | 0.86 | HDAC1 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL2531377 | 0.86 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL13254437 | 0.86 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL2319941 | 0.86 | HDAC3 (0.76) | HDAC1HDAC6HDAC3HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021126974-A1 | BIFUNCTIONAL AGENTS FOR PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| WO-2020191339-A1 | PHOTOAFFINITY PROBES | PROMEGA CORPORATION (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020026054-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2020-02-06 | — | — | WO | disclosed |
| EP-3530290-A1 | ALPHA AMINOACID ESTER-DRUG CONJUGATES HYDROLYSABLE BY CARBOXYLESTERASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| US-9809603-B1 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| WO-2016203337-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203352-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MOHAN M ALAPATI (IN) | 2016-12-22 | — | — | WO | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC3 1/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC3 1/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC3 1/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | HDAC1 1102/4885HDAC6 899/4885HDAC3 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.